In the week of March 9, 2026, 25 holders filed a new Schedule 13D and 56 a new Schedule 13G reporting 5% or more of a company. The largest stake reported that week is ATW Partners Opportunities Management, LLC's 100% of ECD Automotive Design, Inc. (Schedule 13D, March 12, 2026).
The week of 2026-03-09, 25 holders filed a new Schedule 13D and 56 a new Schedule 13G reporting 5% or more of a company, and 0 13D filings stated in Item 4 an intent to influence the company. Open a company for every holder and the purpose each 13D states, quoted.
New Schedule 13D
| Filed | Company | Holder | Percent | Filing |
|---|---|---|---|---|
| 2026-03-12 | ECD Automotive Design, Inc. | ATW Partners Opportunities Management, LLC | 100% | SCHEDULE 13D |
| 2026-03-09 | High Wire Networks, Inc. | O'Leary Dennis M | 80% | SCHEDULE 13D |
| 2026-03-11 | Ellomay Capital Ltd. | O.Y. Nofar Energy Ltd. | 45.9% | SCHEDULE 13D |
| 2026-03-12 | Fold Holdings, Inc. | Fulgur Frontier Capital LP | 37.47% | SCHEDULE 13D |
| 2026-03-13 | Airsculpt Technologies, Inc. | Rollins Aaron | 23.6% | SCHEDULE 13D |
| 2026-03-11 | Highlander Silver Corp. | Augusta Ozama Investment LP | 23.2% | SCHEDULE 13D |
| 2026-03-09 | APEX Tech Acquisition Inc. | Apex Innovation Acquisition Corp. | 21.1% | SCHEDULE 13D |
| 2026-03-12 | GeoPark Limited | Colden Investments S.A. | 20.2% | SCHEDULE 13D |
| 2026-03-10 | SaverOne 2014 Ltd. | VisionWave Holdings, Inc. | 19.99% | SCHEDULE 13D |
| 2026-03-10 | Atlas Trinity Tech Co. | Zhiwei Liu | 17.92% | SCHEDULE 13D |
| 2026-03-10 | 20/20 Biolabs, Inc. | Jonathan M Cohen | 16.8% | SCHEDULE 13D |
| 2026-03-10 | Soundthinking, Inc. | Veradace Capital Management LLC | 16.5% | SCHEDULE 13D |
| 2026-03-13 | Dicks Sporting Goods Inc | Michael E. Stack | 15.42% | SCHEDULE 13D |
| 2026-03-13 | Dicks Sporting Goods Inc | Overbrook235 LLC | 15.39% | SCHEDULE 13D |
| 2026-03-12 | Versamet Royalties Corp | Tether Global Investments Fund, S.I.C.A.F., S.A. | 12.7% | SCHEDULE 13D |
| 2026-03-09 | Huckleberry.ai, Inc. | RPD Fund Management LLC | 11.97% | SCHEDULE 13D |
| 2026-03-12 | Starz Entertainment Corp. | Allen Family Capital, LLC | 10.7% | SCHEDULE 13D |
| 2026-03-12 | Repay Holdings Corporation | Forager Fund, L.P. | 10% | SCHEDULE 13D |
| 2026-03-11 | ZenaTech, Inc. | Jennings Family Investments, Inc. | 9.9% | SCHEDULE 13D |
| 2026-03-09 | Calidi Biotherapeutics, Inc. | Gavrilov Ognian Anguelov | 9.8% | SCHEDULE 13D |
| 2026-03-10 | Tenax Therapeutics Inc | Christopher Thomas Giordano | 6.79% | SCHEDULE 13D |
| 2026-03-12 | Kingstone Companies, Inc. | Gregory Fortunoff | 5.9% | SCHEDULE 13D |
| 2026-03-10 | Perimeter Solutions, Inc. | William N. Thorndike, Jr. | 5.7% | SCHEDULE 13D |
| 2026-03-13 | Diana Shipping Inc. | Taracan Investments S.A. | 5.7% | SCHEDULE 13D |
| 2026-03-12 | BlackLine Inc | Fivespan Partners, LP | 5.1% | SCHEDULE 13D |
New Schedule 13G
| Filed | Company | Holder | Percent | Filing |
|---|---|---|---|---|
| 2026-03-12 | WisdomTree U.S. LargeCap Dividend Fund | Halbert Hargrove Global Advisors, LLC | 24.5% | SCHEDULE 13G |
| 2026-03-13 | Gores Holdings X, Inc. / CI | Gores Sponsor X LLC | 20.3% | SCHEDULE 13G |
| 2026-03-11 | Nine Energy Service, Inc. | Philosophy Capital Management LLC | 18.3% | SCHEDULE 13G |
| 2026-03-10 | J-Long Group Ltd | GTS Securities LLC | 13.6% | SCHEDULE 13G |
| 2026-03-12 | Cantor Equity Partners I, Inc. | Fulgur Frontier Capital LP | 12.2% | SCHEDULE 13G |
| 2026-03-12 | Zenvia Inc. | Perea Capital Partners, LP | 11.57% | SCHEDULE 13G |
| 2026-03-10 | H2o America | ATLAS Infrastructure Partners (UK) Ltd. | 10.84% | SCHEDULE 13G |
| 2026-03-11 | Haymaker Acquisition Corp. 4 | Harraden Circle Investments, LLC | 9.99% | SCHEDULE 13G |
| 2026-03-09 | Tenax Therapeutics Inc | Logos Global Management LP | 9.9% | SCHEDULE 13G |
| 2026-03-09 | Direct Digital Holdings, Inc. | Continuation Capital, Inc. | 9.73% | SCHEDULE 13G |
| 2026-03-12 | Coya Therapeutics, Inc. | Dr. Reddy's Laboratories, Inc. | 9.7% | SCHEDULE 13G |
| 2026-03-12 | Vision Marine Technologies Inc. | Diveroli Investment Group LLC | 9.5% | SCHEDULE 13G |
| 2026-03-10 | VanEck Bitcoin ETF | NEOS Investment Management LLC | 9.24% | SCHEDULE 13G |
| 2026-03-12 | Cero Therapeutics Holdings, Inc. | Tibbs Isaiah | 8.67% | SCHEDULE 13G |
| 2026-03-13 | Cartesian Therapeutics Inc | Squarepoint Ops LLC | 8.3% | SCHEDULE 13G |
| 2026-03-11 | Acadia Healthcare Co Inc | Eric Khrom | 8.09% | SCHEDULE 13G |
| 2026-03-13 | AN2 Therapeutics, Inc. | Vivo Opportunity Fund Holdings, L.P. | 8% | SCHEDULE 13G |
| 2026-03-12 | Nexgel, Inc. | Asymmetry Point LP | 7.49% | SCHEDULE 13G |
| 2026-03-11 | Freightos Ltd | Schreiber Zvi | 7.2% | SCHEDULE 13G |
| 2026-03-10 | Crisp Momentum Inc. | Neorigin Co., Ltd. | 6.86% | SCHEDULE 13G |
| 2026-03-09 | Pulmonx Corp | Soleus Capital Master Fund, L.P. | 6.5% | SCHEDULE 13G |
| 2026-03-10 | 20/20 Biolabs, Inc. | Full Succeed International Limited | 6.3% | SCHEDULE 13G |
| 2026-03-13 | AN2 Therapeutics, Inc. | Millennium Management LLC | 6.3% | SCHEDULE 13G |
| 2026-03-09 | TPG Inc. | Millennium Management LLC | 6.2% | SCHEDULE 13G |
| 2026-03-09 | Rail Vision Ltd. | L.I.A. Pure Capital Ltd. | 6.12% | SCHEDULE 13G |
| 2026-03-13 | ClearPoint Neuro, Inc. | MAK Capital Fund LP | 6.1% | SCHEDULE 13G |
| 2026-03-12 | 1RT Acquisition Corp. | Linden Advisors LP | 5.9% | SCHEDULE 13G |
| 2026-03-13 | KLX Energy Services Holdings, Inc. | Cross Ocean Partners Management LP | 5.9% | SCHEDULE 13G |
| 2026-03-10 | Coursera, Inc. | Pale Fire Capital SICAV a.s. | 5.8% | SCHEDULE 13G |
| 2026-03-10 | Infleqtion, Inc. | BOKA Group Holdings I LP | 5.75% | SCHEDULE 13G |
| 2026-03-11 | Korro Bio, Inc. | Steven A. Cohen | 5.7% | SCHEDULE 13G |
| 2026-03-11 | Kensington Capital Acquisition Corp. VI | Millennium Management LLC | 5.7% | SCHEDULE 13G |
| 2026-03-13 | Mesa Laboratories Inc | Long Path Smaller Companies Fund, LP | 5.6% | SCHEDULE 13G |
| 2026-03-10 | Modular Medical, Inc. | 683 Capital Management, LLC | 5.52% | SCHEDULE 13G |
| 2026-03-11 | Xwell | McCabe James Joseph III | 5.5% | SCHEDULE 13G |
| 2026-03-11 | Vera Therapeutics, Inc. | Deep Track Capital, LP | 5.5% | SCHEDULE 13G |
| 2026-03-13 | Greenland Mines Ltd | Strategic EP, LLC | 5.5% | SCHEDULE 13G |
| 2026-03-11 | Renatus Tactical Acquisition Corp I | Harraden Circle Investments, LLC | 5.45% | SCHEDULE 13G |
| 2026-03-11 | PRESIDIO PRODUCTION Co | BP Energy Company | 5.42% | SCHEDULE 13G |
| 2026-03-10 | Perspective Therapeutics, Inc. | Avidity Partners Management LP | 5.3% | SCHEDULE 13G |
| 2026-03-10 | Blue Moon Metals Inc. | Eric M. Mindich | 5.3% | SCHEDULE 13G |
| 2026-03-11 | Enhanced Group Inc. | Millennium Management LLC | 5.3% | SCHEDULE 13G |
| 2026-03-12 | Phathom Pharmaceuticals, Inc. | Millennium Management LLC | 5.3% | SCHEDULE 13G |
| 2026-03-09 | TaskUs, Inc. | Saba Capital Management, L.P. | 5.27% | SCHEDULE 13G |
| 2026-03-09 | SuperX AI Technology Ltd | Yong Rong (HK) Asset Management Ltd | 5.2% | SCHEDULE 13G |
| 2026-03-10 | Nutex Health, Inc. | Pertento Partners LLP | 5.2% | SCHEDULE 13G |
| 2026-03-13 | SBC Medical Group Holdings Inc | Aikawa Equity Management Co., Ltd. | 5.2% | SCHEDULE 13G |
| 2026-03-12 | Arq, Inc. | Daniel Kaufman | 5.12% | SCHEDULE 13G |
| 2026-03-09 | Bally's Corp | Whitefort Capital Management, LP | 5.1% | SCHEDULE 13G |
| 2026-03-11 | PepGen Inc. | Commodore Capital LP | 5.1% | SCHEDULE 13G |
| 2026-03-12 | Core Scientific, Inc. | Valiant Capital Management, L.P. | 5.1% | SCHEDULE 13G |
| 2026-03-11 | Harrow, Inc. | Daniel Kaufman | 5.04% | SCHEDULE 13G |
| 2026-03-12 | Quantum X Labs Inc. | Capitalink Ltd. | 5.04% | SCHEDULE 13G |
| 2026-03-10 | Sabre Corp | Arini Capital Management Limited | 5.01% | SCHEDULE 13G |
| 2026-03-11 | Codexis, Inc. | Lytton Laurence W | 5% | SCHEDULE 13G |
| 2026-03-11 | New York Times Co-A | Linonia Partners Fund LP | 5% | SCHEDULE 13G |
Stated intent
No 13D this week stated an intent to influence the company.
Tools for this story
Each opens in a new tab. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.